Impax Laboratories, Inc.
IPXL
IPXL was delisted on the 4th of May, 2018.
188 hedge funds and large institutions have $1.42B invested in Impax Laboratories, Inc. in 2018 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 64 increasing their positions, 63 reducing their positions, and 35 closing their positions.
670% more call options, than puts
Call options by funds: $2.13M | Put options by funds: $276K
14% more capital invested
Capital invested by funds: $1.24B → $1.42B (+$172M)
2% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 63
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.33% less ownership
Funds ownership: 100.76% → 98.43% (-2.3%)
6% less funds holding
Funds holding: 200 → 188 (-12)
31% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 35
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$89.8M |
| 2 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$11.6M |
| 3 |
Morgan Stanley
New York
|
+$11M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.99M |
| 5 |
TG
TCW Group
Los Angeles,
California
|
+$6.96M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MC
Maverick Capital
Dallas,
Texas
|
-$64.5M |
| 2 |
Janus Henderson Group
London,
|
-$19.9M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$18.7M |
| 4 |
Renaissance Technologies
New York
|
-$18.4M |
| 5 |
HSBC Holdings
London,
United Kingdom
|
-$7.86M |
IPXL Hedge Fund Activity: Q1 2018 in Review
188 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Impax Laboratories, Inc. (IPXL) for Q1 2018, worth a combined $1.42B — up 14% from $1.24B a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of IPXL and 24 opened new positions — a net loss of 11 holders — while 63 trimmed existing stakes and 64 added.
The largest buyer was Fidelity Investments, adding an estimated $89.8M. The largest seller was Maverick Capital, cutting an estimated $64.5M.
- 188 institutional investors held Impax Laboratories, Inc. (IPXL) as of Q1 2018, down from 200 in Q4 2017.
- Funds reported $1.42B of Impax Laboratories, Inc. stock for Q1 2018, up 14% quarter-over-quarter.
- 24 funds opened new Impax Laboratories, Inc. positions in Q1 2018 and 35 closed out, a net change of -11 holders.
- The largest Impax Laboratories, Inc. buyer in Q1 2018 was Fidelity Investments, an estimated $89.8M added.
- The largest Impax Laboratories, Inc. seller in Q1 2018 was Maverick Capital, an estimated $64.5M sold.
Based on aggregated 13F filings for Q1 2018.